Barrett's Esophagus Clinical Trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 1830 clinical trials
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Routine pediatric vaccines will be given as per local recommendations.There will be 6 study visits:Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated …
- 0 views
- 25 Apr, 2025
Determination of the Optimal Treatment Target in Ulcerative Colitis
Participants with active UC will be randomized in a 2:3:5 ratio to 1 of 3 groups, each with a different treatment target. Treatment targets will be defined as: Group 1: corticosteroid-free symptomatic remission Group 2: corticosteroid-free endoscopic + symptomatic remission Group 3: corticosteroid-free histological + endoscopic + symptomatic remission
- 0 views
- 16 Feb, 2024
- 1 location
v6.10 Sprint Demo - Final
The change in PGA score will be recorded at each of the 4 study visits, for up to
- 0 views
- 09 Aug, 2023
- 6 locations
Computer Vision Syndrome Visual Sequelae
the university students will respond to CVS-F3 survey form and then they will be subjected to complete ophthalmic examination and investigations
- 0 views
- 05 Aug, 2020
Assessment of the Efficacy Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
- 0 views
- 16 Feb, 2024
- 2 locations
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II) (INTRAGO-II)
INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.
- 0 views
- 20 Jul, 2022
- 17 locations
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine).
- 0 views
- 14 Mar, 2022
- 228 locations
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
The present trial will be performed to characterize the dose-response curve for BI 655130 in patients with a history of Generalized Pustular Psoriasis (GPP, per European Rare and Severe Psoriasis Expert Network (ERASPEN) criteria) who are now (at screening and at randomization) presenting with a Generalized Pustular Psoriasis Physician Global …
- 0 views
- 16 Feb, 2024
- 20 locations
Intra-articular Vancomycin Powder in Knee and Hip Arthroplasty
This is a prospective, randomized clinical survey on selected outcome measurements on 1834 subjects who will be recruited in a period of about 2 years.
- 0 views
- 05 Aug, 2020
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort of approximately 38 participants. All participants in this study will continue to be treated until progression of disease, loss of clinical benefit, unacceptable toxicity or withdrawal of consent.
- 0 views
- 16 Feb, 2024
- 18 locations